Update on proprotein convertase subtilisin/kexin type 9 inhibitors, lipoprotein(a) and cardiovascular risk

Curr Opin Lipidol. 2021 Oct 1;32(5):324-327. doi: 10.1097/MOL.0000000000000771.

Authors

Laurent O Martinez¹, Bertrand Perret^{1

2}, Annelise Genoux^{1

2}

Affiliations

¹ I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS).
² Service de Biochimie, Pôle de biologie, Hôpital de Purpan, CHU de Toulouse, Toulouse, France.

PMID: 34472540
DOI: 10.1097/MOL.0000000000000771

No abstract available

MeSH terms

Cardiovascular Diseases* / drug therapy
Heart Disease Risk Factors
Humans
Lipoprotein(a)
Proprotein Convertase 9 / genetics
Risk Factors
Subtilisin*

Substances

Lipoprotein(a)
Proprotein Convertase 9
Subtilisin